XWEL

XWELL, Inc.
CAPPED RATING

XWELL, Inc. (XWEL) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (D+). The rating has held at C for 6 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
C
Factor Score 2.2 / 5.0
Momentum
D+
Factor Score 1.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.2
EV / EBITDA -1.0
Rev Growth YoY -7.1%
Gross Margin 34.3%
Price Return 3M -43.0%
Price Return 12M -37.6%
Catalyst Signal 0.00
Market Cap $5.6M
TTM Revenue $28.3M
Price / Sales 0.2
ROE -361.4%

Historical Factor Score Progression

Held C for 6 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (3.0) D+ (1.7) C (2.2) D+ (1.5) C+ (2.6) C (2.2)
2026-11-08 B- (3.0) D+ (1.7) C (2.2) D+ (1.8) C+ (2.6) C (2.3)
2026-11-01 B- (3.0) D+ (1.7) C (2.4) D+ (1.6) C+ (2.7) C (2.3)
2026-10-25 B- (3.0) D+ (1.7) C (2.3) D+ (1.7) C+ (2.6) C (2.3)
2026-10-18 B- (3.0) D+ (1.7) C (2.3) D+ (1.7) C+ (2.6) C (2.3)
Page 1 of 4